Tdap Given in Pregnancy Protects Infants From Pertussis

Share this content:
Tdap Given in Pregnancy Protects Infants From Pertussis
Tdap Given in Pregnancy Protects Infants From Pertussis

MONDAY, Oct. 2, 2017 (HealthDay News) -- Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination during the third trimester of pregnancy is effective for preventing pertussis in infants in the first months of life, according to a study published online Sept. 28 in Clinical Infectious Diseases.

Tami H. Skoff, from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted a case-control evaluation among pertussis cases <2 months old with onset of cough between Jan. 1, 2011, and Dec. 31, 2014, from six U.S. Emerging Infection Program Network states. Controls were selected by birth certificate and matched by hospital. Data were included for 240 cases and 535 controls.

The researchers found that 7.1 and 16.8 percent of case and control mothers, respectively, received Tdap during the third trimester of pregnancy. For Tdap administered during the third trimester of pregnancy, the multivariable vaccine effectiveness estimate was 77.7 percent. Against hospitalized cases, vaccine effectiveness increased to 90.5 percent.

"Vaccination during pregnancy is an effective way to protect infants during the early months of life," the authors write. "With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptake among pregnant women."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

CDC: Birth Rate for 10- to-14-Year-Olds at Record Low in 2016

CDC: Birth Rate for 10- to-14-Year-Olds at Record ...

Reduction in birth rates for all race and Hispanic origin groups; largest decline in non-Hispanic blacks

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lower mortality seen with lonafarnib monotherapy after 2.2 years compared with no treatment

About 40 Percent of Men Report Experiencing Weight Stigma

About 40 Percent of Men Report Experiencing Weight ...

Experience of weight stigma associated with increased odds of underweight or obesity

is free, fast, and customized just for you!

Already a member?

Sign In Now »